{
  "id": 881096,
  "title": "Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers",
  "url": "https://urgent.news/2026/08/14/capricor-shares-spike-on-ceo-comments-cytokinetics-sues-bristol-myers",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-14T13:28:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/capricor-fda-cytokinetics-lawsuit-valneva-indupro-rusfertide-veppanu/827770/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Cytokinetics brings patent suit against Bristol Myers Squibb, escalating rivalry",
        "url": "https://urgent.news/2026/08/14/cytokinetics-brings-patent-suit-against-bristol-myers-squibb",
        "published": "2026-08-14T17:44:45.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}